Ramos D M, Berston E D, Kramer R H
Department of Stomatology, University of California, San Francisco 94143.
Cancer Res. 1990 Feb 1;50(3):728-34.
As tumor cells invade surrounding tissue, they adhere to various extracellular matrix components. Previously we reported that B16-BL6 melanoma cell adhesion to both basement membrane and purified protein substrates was blocked by antibody to beta 1-integrin adhesion receptors (R. H. Kramer et al., Cancer Res., 49: 393-402, 1989). In the present study we found, using immunofluorescent staining, that beta 1-integrin complexes were colocalized with vinculin in focal adhesion plaques on laminin, type IV collagen, and fibronectin substrates. To identify potential adhesion receptors on B16 cells, the cells were surface-labeled with 125I, solubilized with detergent, and chromatographed on laminin-, type IV collagen-, and fibronectin-Sepharose columns. On laminin-Sepharose, an integrin heterodimer complex was eluted with EDTA that contained a beta 1 chain at Mr 120,000 and an alpha subunit at Mr 140,000 (nonreduced). This complex was specific for laminin and failed to bind to collagen- or fibronectin-Sepharose columns. Immunoprecipitation with specific monoclonal antibody identified this complex as alpha 6 beta 1 (VLA-6). Furthermore, monoclonal antibody to the alpha 6 beta 1 complex effectively blocked the attachment of B16-BL6 cells to laminin but did not affect adhesion to fibronectin or type IV collagen. We recovered a different integrin complex from type IV collagen-Sepharose columns that was composed of a beta 1 chain and an alpha chain of Mr 180,000 (nonreduced). This same complex also exhibited a weak affinity for laminin-affinity chromatography. The laminin-binding complex and the type IV collagen-binding complex were clearly distinct from the fibronectin-binding receptor and were not eluted by arginyl-glycyl-aspartate-containing peptides. The results suggest that the B16 melanoma cells express multiple integrin-related receptors that appear to mediate cell adhesion to basement membrane matrices.
随着肿瘤细胞侵入周围组织,它们会黏附于各种细胞外基质成分。此前我们报道过,抗β1整合素黏附受体的抗体可阻断B16 - BL6黑色素瘤细胞与基底膜及纯化蛋白底物的黏附(R. H. 克莱默等人,《癌症研究》,49: 393 - 402, 1989)。在本研究中,我们通过免疫荧光染色发现,β1整合素复合物与纽蛋白在层粘连蛋白、IV型胶原和纤连蛋白底物上的黏着斑中共定位。为了鉴定B16细胞上潜在的黏附受体,用125I对细胞进行表面标记,用去污剂使其溶解,然后在层粘连蛋白 - 琼脂糖柱、IV型胶原 - 琼脂糖柱和纤连蛋白 - 琼脂糖柱上进行层析。在层粘连蛋白 - 琼脂糖柱上,一种整合素异二聚体复合物被EDTA洗脱,该复合物在非还原状态下包含一条分子量为120,000的β1链和一条分子量为140,000的α亚基。这种复合物对层粘连蛋白具有特异性,不能与胶原 - 琼脂糖柱或纤连蛋白 - 琼脂糖柱结合。用特异性单克隆抗体进行免疫沉淀鉴定该复合物为α6β1(VLA - 6)。此外,针对α6β1复合物的单克隆抗体有效地阻断了B16 - BL6细胞与层粘连蛋白的附着,但不影响其与纤连蛋白或IV型胶原的黏附。我们从IV型胶原 - 琼脂糖柱上回收了一种不同的整合素复合物,它由一条β1链和一条分子量为180,000的α链组成(非还原状态)。这种相同的复合物对层粘连蛋白亲和层析也表现出较弱的亲和力。层粘连蛋白结合复合物和IV型胶原结合复合物与纤连蛋白结合受体明显不同,且不会被含精氨酰 - 甘氨酰 - 天冬氨酸的肽洗脱。结果表明,B16黑色素瘤细胞表达多种整合素相关受体,这些受体似乎介导细胞与基底膜基质的黏附。